EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Klinische Studie (Phase II)Open Access · CC BY 4.0

Clinical Management of Patients With Relapsed/Refractory Multiple Myeloma Treated With Talquetamab

Ajai Chari, Amrita Krishnan, Leo Rasche, Jing Christine Ye, Alfred Garfall, Rakesh Popat, Brea Lipe, Xiang Qin, Michela Campagna, Tara Masterson, Chalmer Tomlinson, Brandi Hilder und 7 weitere

Clinical Lymphoma Myeloma and Leukemia · 2024-10 · 24 (10) · 665-693.e14

DOI: 10.1016/j.clml.2024.05.003 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2024-10. Verfasst von Ajai Chari und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Hematology, and Medical Oncology and Tisch Cancer Institute, Mount Sinai School of Medicine, New York, NY. Electronic address…. Hauptthemen laut MEDLINE: Antibodies, Bispecific, Multiple Myeloma. Die Arbeit wurde bisher 53-mal zitiert (Crossref) und nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Talquetamab is a bispecific antibody targeting the multiple myeloma-associated antigen G protein-coupled receptor family C group 5 member D (GPRC5D). In the phase 1/2 MonumenTAL-1 trial (NCT03399799/NCT04634552), overall responses rates were > 71% in patients with triple-class exposed relapsed/refractory multiple myeloma (RRMM). Due to the distribution of the target antigen, a unique pattern of GPRC5D-associated adverse events (AEs) was observed, together with T-cell redirection-associated AEs. Management strategies for talquetamab-associated AEs are described. DISCUSSION: GPRC5D-associated AEs included dermatologic (rash, nonrash, and nail toxicities) and oral AEs (dysgeusia, dysphagia, and dry mouth). The incidence of cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) were consistent with other T-cell redirection therapies. The incidence of high-grade infections was lower than observed with B-cell maturation antigen-targeting bispecific antibodies, with less frequent use of intravenous immunoglobulin required. GPRC5D-associated AEs were mostly low grade and led to few discontinuations. Skin toxicities were managed with emollients, topical corticosteroids, and oral corticosteroids (for high-grade, persistent, or AEs that progress). Nail toxicities were commonly managed with emollients. Based on investigator experience, dose modification may be effective for controlling oral events. Observation for potential weight changes is required. Infections were managed per standard of care. CRS and ICANS were effectively managed, consistent with other trials of T-cell redirection therapies. CONCLUSION: Although talquetamab had a distinct safety profile, AEs were considered clinically manageable and mostly low grade. With appropriate education and support, health care practitioners can ensure patients with RRMM maintain quality of life and treatment adherence. VIDEO ABSTRACT.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, BispecificMultiple MyelomaFemaleHumansMaleDisease Management

Stichwörter der Autor:innen

Bispecific antibodyDermatologic toxicitiesGPRC5DInfectionsOral events

Substanzen

Antibodies, Bispecific

Autor:innen und Institutionen

  • Department of Medicine, Hematology, and Medical Oncology and Tisch Cancer Institute, Mount Sinai School of Medicine, New York, NY. Electronic address: ajai.chari@ucsf.edu.
  • Judy and Bernard Briskin Myeloma Center, City of Hope Comprehensive Cancer Center, Duarte, CA.
  • Department of Internal Medicine II, University Hospital of Würzburg, Würzburg, Germany.
  • Department of Lymphoma - Myeloma, Division of Cancer Medicine, MD Anderson Cancer Center, University of Texas, Houston, TX.
  • Department of Medicine, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA.
  • Hematology Department, University College London Hospitals NHS Foundation Trust, London, UK.

Zitieren

APA

Chari, A., Krishnan, A., Rasche, L., Ye, J. C., Garfall, A., Popat, R., Lipe, B., Qin, X., Campagna, M., Masterson, T., Tomlinson, C., Hilder, B., Tolbert, J., Renaud, T., Smit, M. D., Gray, K., Kane, C., Heuck, C., & van de Donk, N. W. C. J. (2024). Clinical Management of Patients With Relapsed/Refractory Multiple Myeloma Treated With Talquetamab. Clinical Lymphoma Myeloma and Leukemia, 24(10), 665-693.e14. https://doi.org/10.1016/j.clml.2024.05.003

Vancouver

Chari A, Krishnan A, Rasche L, Ye JC, Garfall A, Popat R, et al. Clinical Management of Patients With Relapsed/Refractory Multiple Myeloma Treated With Talquetamab. Clinical Lymphoma Myeloma and Leukemia. 2024;24(10):665-693.e14. doi:10.1016/j.clml.2024.05.003

BibTeX
@article{Chari2024,
  author = {Chari, Ajai and Krishnan, Amrita and Rasche, Leo and Ye, Jing Christine and Garfall, Alfred and Popat, Rakesh and Lipe, Brea and Qin, Xiang and Campagna, Michela and Masterson, Tara and Tomlinson, Chalmer and Hilder, Brandi and Tolbert, Jaszianne and Renaud, Thomas and Smit, M Damiette and Gray, Kathleen and Kane, Colleen and Heuck, Christoph and van de Donk, Niels W C J},
  title = {Clinical Management of Patients With Relapsed/Refractory Multiple Myeloma Treated With Talquetamab},
  journal = {Clinical Lymphoma Myeloma and Leukemia},
  year = {2024},
  volume = {24},
  number = {10},
  pages = {665--693.e14},
  doi = {10.1016/j.clml.2024.05.003}
}
Kostenlos starten →